{"id":"NCT00800735","sponsor":"Hoffmann-La Roche","briefTitle":"A Study of PEGASYS (Pegylated-interferon Alfa-2a) With or Without Ribavirin in Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols","officialTitle":"An Open-label, Multicenter Protocol Providing Pegylated-interferon Alfa-2a (PEGASYS®) as Monotherapy or in Combination With Ribavirin (COPEGUS®) for Patients With Chronic Hepatitis C Who Have Participated in Previous Roche or Roche Partner Protocols","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2009-04","primaryCompletion":"2012-03","completion":"2012-03","firstPosted":"2008-12-02","resultsPosted":"2013-09-13","lastUpdate":"2013-10-30"},"enrollment":30,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Hepatitis C, Chronic"],"interventions":[{"type":"DRUG","name":"Pegylated-interferon alfa-2a","otherNames":["PEG-IFN alfa-2a","Pegasys"]},{"type":"DRUG","name":"Ribavirin","otherNames":["Copegus","Ro 20-9963"]}],"arms":[{"label":"Pegylated-interferon alfa-2a plus ribavirin","type":"EXPERIMENTAL"}],"summary":"This single arm study will provide treatment or re-treatment with PEGASYS as monotherapy or in combination with ribavirin (Copegus), to patients with chronic hepatitis C (CHC) who have participated in a previous Roche or Roche partner protocol where access to treatment or re-treatment was promised or deemed appropriate following completion of the original protocol ('donor' protocol). Patients who qualify for treatment or re-treatment will begin PEGASYS monotherapy, at a maximum dose of 180 µg weekly, or combination therapy with Copegus, 800-1200 mg daily, as continuation of treatment after the wash-out period defined in their donor protocol. PEGASYS treatment is not to exceed the approved treatment duration of 48 weeks in genotype G1 with a treatment-free follow up period of 24 weeks.","primaryOutcome":{"measure":"Percentage of Participants Who Experienced at Least 1 Adverse Event.","timeFrame":"Baseline through 24 weeks after the end of treatment (up to 72 weeks)","effectByArm":[{"arm":"Pegylated-interferon Alfa-2a Plus Ribavirin","deltaMin":80,"sd":null}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":2,"exclusionCount":1},"locations":{"siteCount":23,"countries":["United States","Austria","Canada","France","Germany","Spain"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":30},"commonTop":["Fatigue","Pruritus","Nausea","Chills","Headache"]}}